title: Bevacizumab-associated osteonecrosis of the jaw.
authors.forename: S
authors.initials: S
authors.lastname: Greuter
authors.forename: F
authors.initials: F
authors.lastname: Schmid
authors.forename: T
authors.initials: T
authors.lastname: Ruhstaller
authors.forename: B
authors.initials: B
authors.lastname: Thuerlimann
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced*; D015523:Maxillary Sinusitis / Q000150:complications; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010020:Osteonecrosis / Q000139:chemically induced*; D014076:Tooth Diseases / Q000150:complications
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004317:Doxorubicin